Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

10.44
-0.4400-4.04%
Post-market: 10.550.1100+1.05%19:59 EDT
Volume:1.27M
Turnover:13.48M
Market Cap:798.85M
PE:-7.26
High:11.25
Open:11.02
Low:10.37
Close:10.88
52wk High:14.00
52wk Low:4.35
Shares:76.52M
Float Shares:60.06M
Volume Ratio:1.35
T/O Rate:2.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4390
EPS(LYR):-0.7210
ROE:-81.84%
ROA:-28.64%
PB:6.33
PE(LYR):-14.48

Loading ...

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 09

Candel Therapeutics Posts Corporate Presentation on Cancer Immunotherapy Pipeline Led by Can-2409 and Can-3110 Programs

Reuters
·
Jul 08

Candel Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Jul 07

Candel Therapeutics CTO Seshu Tyagarajan Sells 7,000 Common Shares for $70,151.20

Reuters
·
Jul 02

Candel Therapeutics Grants New Hire Options for 25,000 Shares at $10.3 Each

Reuters
·
Jul 02

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 02

Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-cancer Drug

Dow Jones
·
Jun 30

Candel Therapeutics Launches Phase 3 Aurora Trial of Can-2409 Combo in Advanced NSCLC

Reuters
·
Jun 30

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 Aurora Trial Evaluating Aglatimagene Besadenovec (can-2409) in Advanced Non-small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

THOMSON REUTERS
·
Jun 30

Candel Therapeutics Names Mark Sims Chief Commercial Officer

Reuters
·
Jun 25

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

THOMSON REUTERS
·
Jun 25

Candel Therapeutics Stockholders Approve Directors and Auditor

TIPRANKS
·
Jun 25

Candel Therapeutics Shareholders Elected Four Class II Directors at Annual Meeting

Reuters
·
Jun 25

Candel Therapeutics Updates Employment Agreement with Chief Financial Officer

TIPRANKS
·
Jun 17

Candel Therapeutics CFO Schoch employment agreement keeps base salary at $468,600, bonus target 40%

Reuters
·
Jun 17

Analyst Reiterates Buy Rating on Strengthened Phase 3 Data for Aglatimagene Besadenovec, Maintains $23 Price Target

TIPRANKS
·
Jun 03

Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene

TIPRANKS
·
Jun 02

Candel Therapeutics says Phase 3 trial shows 30% disease-free survival gain for CAN-2409 in localized prostate cancer

Reuters
·
Jun 02

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

GlobeNewswire
·
Jun 02

Candel Therapeutics grants inducement stock options for 63,000 shares at $8.3 each

Reuters
·
Jun 02